Intercytex Update at AGM

Intercytex Group plc (AIM: ICX) (“Intercytex”), a developer of regenerative medicine products, will today provide an update to shareholders on developments in relation to its ongoing strategic review at the Company’s Annual General Meeting (“AGM”).

Since the announcement on 20 February 2009 that it was reviewing strategic options, the Company has held discussions with a number of interested parties. Although at an early stage, the Company can confirm that it has received a number of approaches which may or may not lead to an offer for the Company or certain business assets. It is the Board’s intention to ensure that all interested parties are brought rapidly to the same point in the process, such that the Board will be in a position to compare all potential offers, and to maximise shareholder value.

A further update will be provided to shareholders in due course